SAĞLIKLI VERİCİLERİN YAŞI TOPLANAN PERİFERİK KÖK HÜCRE MİKTARI ÜZERİNDE ETKİLİ MİDİR? Does the Age of the Healthy Donors Related With the Amount of Stem Cells Collected With GCSF?
Abstract
ÖZET
Amaç: Bu çalışmada sağlıklı kök hücre vericilerinin yaşının periferik kandan toplanan CD34+ kök hücre miktarı
üzerinde etkisinin olup olmadığı incelendi.
Gereç ve Yöntemler: Bu retrospektif çalışma için, 2016 - 2018 yılları arasında gönüllü olarak merkezimizde
kök hücre veren sağlıklı vericilerin dosyaları taranmıştır. Çalışma 32 erkek ve 21 kadın olmak üzere toplam 53
vericiyi kapsamaktadır. Vericiler 50 yaş altı ve 50 yaş üstü olarak iki gruba ayrıldı. Tüm vericiler lenograstim/
filgrastim kullanılarak mobilize edildi. Periferik kan CD34+ kök hücre sayımları ön ölçümlere göre 20x10^6/L
‘den fazla olan vericilere Fresenius (Bad Homburg, Almanya) cihazı ile mobilizasyon prosedürü uygulandı. İşlem
sonrası toplanan CD34+ ler sayıldı ve vericilerin yaş grupları ile ilişkisi incelendi.
Bulgular: Çalışmaya 53 sağlıklı verici dahil edildi. CD34+ kök hücrelerin ön ölçüm değerleri açısından gruplar
arasında istatistiksel olarak anlamlı fark bulunmadı. Genç yaş grubunda (50 yaş altı olan grup) birinci ve ikinci
günlerde yapılan erken ölçümler arasında istatistiksel olarak anlamlı bir fark bulunmazken, erken ölçümlerde
ikinci günde yaşı 50’nin üzerinde olan grupta ilk güne göre istatistiksel olarak anlamlı derecede düşük sonuç
ortaya çıktı. Vücut ağırlığı başına toplanan CD34+ kök hücre sayısı açısından gruplar arasında istatistiksel olarak
anlamlı fark yoktu. Toplanan CD34+ kök hücre sayısı açısından gruplar arasında istatistiksel olarak anlamlı fark
bulunmadı. Kemik ağrısı her iki grupta en sık rastlanan yan etkiydi.
Sonuç: Sonuç olarak, verici yaşının mobilizasyonun başarısız olmasına neden olabilecek bir faktör olmadığını
ve benzer miktarlarda periferik kan kök hücrelerinin hem genç hem de yaşlı vericilerde toplanabileceğini belirledik.
Anahtar kelimeler: Kök hücre transplantasyonu; Lenograstim; Filgrastim.
ABSTRACT
Aim: The present study aimed to investigate whether age of the healthy stem cell donors has an impact on the
amount of collected CD34+ stem cells from the peripheral blood.
Material and Methods: We have scanned the medical records of the volunteer donors who donated stem
cells between the years 2016 to 2018 in our instution for this retrospective study. The present study involved
totally 53 donors containing 32 males and 21 females. The donors were divided into two groups as aged below
and over 50 years. All the donors were mobilized using lenograstim/filgrastim. Mobilization procedure was
performed by Fresenius (Bad Homburg, Almanya) device in the donors from whom CD34+ peripheral blood
stem cells higher than 20x10^6/L according to the early measurement. The number of the CD34+ stem cells
were counted following the procedure and the relationship between the number of the CD34+ stem cells and
age of the donors was analyzed.
Results: The study included 53 healthy donors. No statistically significant difference was found between the
groups with respect to early measurement values of CD34+ stem cells. No statistically significant result was
found between the early measurement values obtained at the first and second days in the healthy younger
group (the group aged below 50 years) whereas a statistically significant different result was obtained in the
second day compared with the first day in the group aged over 50 years. No statistically significant difference
was detected between the groups with respect to the amount of collected CD34+ stem cells per kg (bod
weight). No statistically significant difference was determined between the groups regarding the amount of
CD34+ stem cells. The bone pain was the most commonly found side effect.
Conclusion: As a conclusion, we have determined in this retrospective study that age is not a factor that may
cause a failure of mobilization and that similar amounts of peripheral blood stem cells could be collected in
both younger and older donors.
Keywords: Stem cell transplantation; Lenograstim; Filgrastim.
References
- 1. Pandey T, Thomas S, Heller MT. Current Indications, Techniques, and Imaging Findings of Stem Cell Treatment and Bone Marrow Transplant. Radiol Clin North Am. 2016;54(2):375-96. 2. Pang WW, Schrier SL. Anemia in the elderly. Curr Opin Hematol. 2012;19(3):133-40. 3. Montecino-Rodriguez E, Berent-Maoz B, Dorshkind K. Causes, consequences, and reversal of immune system aging. J Clin Invest. 2013;123(3):958-65. 4. Lichtman MA, Rowe JM. The relationship of patient age to the pathobiology of the clonal myeloid diseases. Semin Oncol. 2004;31(2):185-97. 5. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78(1):21-33. 6. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006;107(1):265-76. 7. Vose JM, Bierman PJ, Lynch JC, Atkinson K, Juttner C, Hanania CE, et al. Transplantation of highly purified CD34+Thy-1+ hematopoietic stem cells in patients with metastatic breast cancer. Biol Blood Marrow Transplant. 2000;6(3):262-71. 8. Bojanić I, Cepulić BG, Mazić S. Collection of hematopoietic progenitor cells from healthy donors. Acta Med Croatica. 2009;63(3):237-44. 9. Artz AS. Older patients/older donors: choosing wisely. Hematology Am Soc Hematol Educ Program. 2013;70-5. 10. Muschler GF, Nitto H, Boehm CA, Easley KA. Age- and gender-related changes in the cellularity of human bone marrow and the prevalence of osteoblastic progenitors. J Orthop Res. 2001;19(1):117-25.
Abstract
References
- 1. Pandey T, Thomas S, Heller MT. Current Indications, Techniques, and Imaging Findings of Stem Cell Treatment and Bone Marrow Transplant. Radiol Clin North Am. 2016;54(2):375-96. 2. Pang WW, Schrier SL. Anemia in the elderly. Curr Opin Hematol. 2012;19(3):133-40. 3. Montecino-Rodriguez E, Berent-Maoz B, Dorshkind K. Causes, consequences, and reversal of immune system aging. J Clin Invest. 2013;123(3):958-65. 4. Lichtman MA, Rowe JM. The relationship of patient age to the pathobiology of the clonal myeloid diseases. Semin Oncol. 2004;31(2):185-97. 5. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78(1):21-33. 6. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006;107(1):265-76. 7. Vose JM, Bierman PJ, Lynch JC, Atkinson K, Juttner C, Hanania CE, et al. Transplantation of highly purified CD34+Thy-1+ hematopoietic stem cells in patients with metastatic breast cancer. Biol Blood Marrow Transplant. 2000;6(3):262-71. 8. Bojanić I, Cepulić BG, Mazić S. Collection of hematopoietic progenitor cells from healthy donors. Acta Med Croatica. 2009;63(3):237-44. 9. Artz AS. Older patients/older donors: choosing wisely. Hematology Am Soc Hematol Educ Program. 2013;70-5. 10. Muschler GF, Nitto H, Boehm CA, Easley KA. Age- and gender-related changes in the cellularity of human bone marrow and the prevalence of osteoblastic progenitors. J Orthop Res. 2001;19(1):117-25.
Details
| Primary Language | Turkish |
|---|---|
| Subjects | Health Care Administration |
| Journal Section | Original Research |
| Authors | |
| Publication Date | March 25, 2020 |
| Published in Issue | Year 2020 Volume: 10 Issue: 1 |